InjenTa Duo Tablets 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Vivozone Pharmaceutical Co., Ltd.
MFDS item code 202001551 · Approved 2020.03.05
This product's status changed to Expired on 2025.03.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is mainly used to help control blood sugar levels in adult patients with type 2 diabetes. It is administered as an adjunct to dietary therapy and exercise, and can be used when it is difficult to control blood sugar levels alone in patients who have not previously received diabetes medication. Additionally, it can replace the combination of linagliptin and metformin or be co-administered with insulin when the combination of insulin and metformin is insufficient. It can also be used in conjunction with this medication when blood sugar control is inadequate even with the maximum dose of metformin and empagliflozin. Thus, it is used to effectively control blood sugar in combination with various therapies tailored to the patient's condition.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).
This medication may cause a rare but serious side effect known as lactic acidosis, so caution is needed. Lactic acidosis occurs when there is a buildup of lactic acid in the body, which can be life-threatening if not treated. Individuals allergic to this drug's active ingredients or any components should not take it. Type 1 diabetes patients, those with lactic acidosis or diabetic ketoacidosis, and people with severe renal impairment should also avoid this medication. Avoid this drug if you have conditions that can affect kidney function, such as severe infections, dehydration, or acute myocardial infarction. Patients with impaired liver function or gastrointestinal disorders should refrain from using this drug. Pregnant or breastfeeding women are advised not to use this drug. When using this medication in conjunction with other blood glucose-lowering agents, caution is necessary due to the risk of hypoglycemia. Particularly when combined with sulfonylureas or insulin, the risk of hypoglycemia may increase and dose adjustments may be needed. The usage and dosage of this drug should be adjusted based on kidney function, and regular kidney function tests are necessary. This medication may need to be temporarily discontinued before and after acute illnesses or surgeries, so follow your doctor's instructions. If you experience sudden abdominal pain, muscle weakness, difficulty breathing, or lethargy while taking this drug, go to the hospital immediately. This drug may lower vitamin B12 levels, thus vitamin B12 testing may be required during long-term use. It is advisable to avoid alcohol consumption while taking this medication, as alcohol can increase the risk of lactic acidosis. If iodine contrast media is to be used during radiological examinations, this drug should be discontinued before and after the test and kidney function must be checked. The elderly should take this medication with particular caution due to the potential for reduced kidney function, and dosage adjustments and regular testing are needed. This medication is not recommended for children or adolescents as safety and effectiveness have not been sufficiently proven. If skin blisters or rashes occur while taking this medication, consult your doctor immediately. In case of overdose, the risk of lactic acidosis increases, so it is essential to adhere to the prescribed dosage, and immediate medical attention is required in the event of overdose.
Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, vitamin B12 reduction and deficiency, hypoglycemia, taste disorders, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid-like conditions, severe arthritis with disability, rhabdomyolysis, increased lipase, increased amylase, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, cerebral infarction, headache, sensory abnormalities, post-herpetic neuralgia, hemiplegia, syncope, drowsiness, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorders, nosebleed, benign prostatic hyperplasia, insomnia, depression, hypertension, benign, malignant and unspecified neoplasms, myelodysplastic syndrome, confused state, nocturia, dermatitis, pruritus, anxiety, erectile dysfunction, goiter, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, osteoarthritis, limb pain, rotator cuff syndrome, dizziness, diabetic neuropathy, subdural effusion, corneal abrasion, falls, upper limb fractures, nosebleed, vocal cord polyp, hearing loss, hypercholesterolemia, hypochromia, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, increased ALT, increased AST, increased triglycerides in blood, hyperhidrosis, hair loss, dermatitis, skin lesions, insomnia, depression, anxiety, dizziness, hypertension
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is between 1 degree and 30 degrees Celsius at room temperature. This will help maintain the drug's effectiveness longer.
Biconvex oval film-coated tablet in bright yellow color
60 tablets/box [10 tablets/PTP Χ 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Vivozone Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.